PLOD1

Across TCGA pan-cancer cohorts, PLOD1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PLOD1 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PLOD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PLOD1 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and GBM are the cancer types where PLOD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	III,IV	0.470	0.875	.001	69	view →
PDAC	DFS	Tertile	All	0.270	0.492	<.001	33	view →
GBM	DFS	Tertile	All	0.244	0.470	.010	14	view →
LUAD	OS	Median	II,III,IV	0.862	1.000	.004	9	view →
UCEC	DFS	Median	All	0.857	0.951	.025	4	view →
LSCC	OS	Quartile	II,III,IV	0.641	0.939	.030	4	view →
HNSC	DFS	Tertile	IV	0.586	0.853	.032	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PLOD1–CCRCC (OS)

Open the CCRCC breakdown →